Table A12.2Comparison of ARR Results between Base Case Model and Adjusted Models Using Select Covariates

TreatmentBase Case ResultsCovariate: Time Since
Symptom Onset
Covariate: Mean
Relapses
Covariate: Baseline
EDSS
Covariate: Treatment
Duration
95% CrI95% CrI95% CrI95% CrI95% CrI
Alemtuzumab 12 mg0.30(0.25, 0.37)0.31(0.25, 0.38)0.30(0.24, 0.37)0.31(0.24, 0.38)0.30(0.24, 0.37)
Alemtuzumab 24 mg0.17(0.1, 0.26)0.17(0.11, 0.28)0.17(0.1, 0.26)0.17(0.1, 0.27)0.17(0.1, 0.26)
Dimethyl fumarate 240 mg0.50(0.42, 0.59)0.51(0.43, 0.6)0.50(0.42, 0.6)0.51(0.42, 0.61)0.50(0.42, 0.6)
Fingolimod 0.5 mg0.44(0.37, 0.53)0.45(0.36, 0.56)0.43(0.33, 0.55)0.44(0.36, 0.53)0.44(0.37, 0.53)
Glatiramer acetate 20 mg0.67(0.6, 0.74)0.68(0.59, 0.78)0.67(0.59, 0.75)0.67(0.57, 0.79)0.66(0.59, 0.74)
Interferon beta-1a 30 mcg0.87(0.76, 0.98)0.88(0.76, 1.03)0.86(0.75, 0.99)0.87(0.76, 1.01)0.86(0.76, 0.98)
Interferon beta-1a 60 mcg0.91(0.75, 1.11)0.92(0.74, 1.16)0.91(0.73, 1.13)0.92(0.74, 1.14)0.91(0.74, 1.13)
Interferon beta-1a 22 mcg0.71(0.6, 0.83)0.72(0.6, 0.85)0.71(0.59, 0.85)0.71(0.59, 0.86)0.71(0.59, 0.84)
Interferon beta-1a 44 mcg0.67(0.59, 0.76)0.69(0.6, 0.79)0.67(0.58, 0.77)0.68(0.58, 0.8)0.67(0.59, 0.76)
Interferon beta-1b 250 mcg0.67(0.59, 0.77)0.69(0.58, 0.81)0.68(0.59, 0.78)0.68(0.56, 0.83)0.67(0.57, 0.77)
Natalizumab 300 mg0.32(0.26, 0.38)0.31(0.26, 0.38)0.32(0.26, 0.39)0.31(0.26, 0.38)0.31(0.26, 0.38)
Teriflunomide 7 mg0.69(0.56, 0.83)0.72(0.54, 0.98)0.68(0.56, 0.84)0.70(0.55, 0.88)0.69(0.56, 0.84)
Teriflunomide 14 mg0.68(0.56, 0.83)0.72(0.53, 0.98)0.68(0.55, 0.84)0.69(0.54, 0.89)0.68(0.56, 0.84)

ARR = annualized relapse rate; CrI = credible interval; EDSS = Expanded Disability Status Scale; mcg = microgram; mg = milligram.

From: APPENDIX 12, SUMMARY OF RESULTS FROM SUBGROUP ANALYSES

Cover of Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis
Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis [Internet].
CADTH Therapeutic Review, No. 1.2B.
Copyright © CADTH March 2013.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.